ASOPRS Fall Symposium to Feature Presentations on Innovations, Diversity and Food


The American Society of Ophthalmic Plastic & Reconstructive Surgery Fall 2021 Scientific Symposium will feature presentations on innovations in eye and face surgery, social justice and diversity, and more.

Both in person in New Orleans, Louisiana and online virtually, the American Society of Ophthalmic Plastic & Reconstructive Surgery (ASOPRS) will meet for the Fall Scientific Symposium, November 11-12, ahead of AAO 2021. , the annual meeting of the American Academy of Ophthalmology.

The meeting starts both days with presentations from young members of ASOPRS (YASPORS). These members have 8 years or less of experience after graduating from an ASOPRS approved scholarship. Some of the topics presented by these members are “Orbital inflammation after COVID-19 vaccination”, “Psychogenic ptosis”, “Quality of life related to patient-reported tearing” and “Epidemiology of ophthalmic trauma in a trauma center in level 1 major. in the United States: the Denver Health Ophthalmic Trauma Registry (DHOTR).

Neal Barnard, MD, FACC, Assistant Professor of Medicine, George Washington University School of Medicine, and Chair, Physicians Committee for Responsible Medicine, will participate in 2 presentations: the ASOPRS Michael J. Hawes Foundation Conference on “Power Foods for the Brain , ”And“ Your Body in Balance: The New Science of Food, Hormones and Health ”.

The symposium will also feature Kris Moe, MD, FACS, Professor, President, Facial Plastic Surgery, University of Washington at Seattle. On the first day he will present the ASOPRS Ralph E. Wesley Foundation lecture, “Transorbital Neuroendoscopic Surgery: The Orbit as a Gateway to the Skull and Brain”, and on the second day he will present “Technical Aids in Orbital Reconstruction”.

Throughout the remainder of the symposium, presentations will be divided into pediatric and lacrimal session; 2 eyelid sessions; 2 aesthetic sessions; 2 orbit sessions; an oncology session; a session on social justice, diversity and distribution of oculofacial plastic surgeons; a practice management session; and a session on thyroid eye disease. Last year, the FDA approved the first treatment for thyroid eye disease, teprotumumab (Tepezza), which changed the therapeutic landscape.

Program chairs highlighted the session on social justice and diversity, which includes timely presentations on representation in oculoplasty, transgender care, assault trauma and social determinants, and social and medical factors associated with loss of the eye.

Finally, the symposium will include 2 panels. On the first day, a panel will discuss “Industry and innovation in oculofacial plastic surgery” and on the second day, a second panel will discuss “Administrative leadership”.


Comments are closed.